Bristol Myers returns to Immatics for a dual-targeting cancer drug
Bristol Myers' acquisition of Celgene immediately made the big pharma a top player in the development of cancer cell therapies. Since the deal closed, Bristol Myers h...
Mastering ADC Bioconjugation: From DAR Control to Efficient Free Payload Removal
Continue readingAdvertisement
Advertisement
Advertisement
IBI – International Biopharmaceutical Industry was established to fill in the void for effective marketing and communication between all stakeholders in the Life sciences sector globally.